Vnitr Lek 2019, 65(11):694-697 | DOI: 10.36290/vnl.2019.120

Why rapid achievement of goal blood pressure is important in the treatment of arterial hypertension

Peter Wohlfahrt*, Renata Cífková
Centrum kardiovaskulární prevence 1. LF UK a Thomayerovy nemocnice, Praha

Currently, there is a change in the algorithm of hypertension treatment, introducing its simplification. While in the past a careful stepwise titration of antihypertensive drugs was used, the current European Society of Hypertension Guidelines prefer a more aggressive and rapid approach to combination treatment as the initial step with the aim to achieve the goal blood pressure within three months. This review summarizes changes in recommendations and evidence supporting a more aggressive treatment of hypertension.

Keywords: combination treatment; goal blood pressure; hypertension

Received: September 12, 2019; Accepted: September 19, 2019; Published: November 1, 2019  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Wohlfahrt P, Cífková R. Why rapid achievement of goal blood pressure is important in the treatment of arterial hypertension. Vnitr Lek. 2019;65(11):694-697. doi: 10.36290/vnl.2019.120.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Lawes CM, Vander Hoorn S, Rodgers A. [International Society of Hypertension]. Global burden of blood-pressure-related disease, 2001. Lancet 2008; 371(9623): 1513-1518. Dostupné z DOI: <http://doi:10.1016/S0140-6736(08)60655-8>. Go to original source... Go to PubMed...
    2. [NCD Risk Factor Collaboration (NCD-RisC)]. Long-term and recent trends in hypertension awareness, treatment, and control in 12 high-income countries: an analysis of 123 nationally representative surveys. Lancet 2019; 394(10199): 639-651. Dostupné z DOI: <http://doi:10.1016/S0140-6736(19)31145-6>. Go to original source... Go to PubMed...
    3. Geldsetzer P, Manne-Goehler J, Marcus ME et al. The state of hypertension care in 44 low-income and middle-income countries: a cross-sectional study of nationally representative individual-level data from 1.1 million adults. Lancet 2019; 394(10199): 652-662. Dostupné z DOI: <http://doi:10.1016/S0140-6736(19)30955-9>. Go to original source... Go to PubMed...
    4. Cifkova R, Bruthans J, Wohlfahrt P et al. 30-year trends in blood pressure, prevalence, awareness, treatment and control of hypertension in the Czech republic. The Czech Monica and Czech Post-Monica studies. J Hypertens 2019; 37:e47. Dostupné z DOI: <http://doi:10.1097/01.hjh.0000570844.48162.8b>. Go to original source...
    5. Williams B, Mancia G, Spiering W et al. [ESC Scientific Document Group]. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J 2018; 39(33): 3021-3104. Dostupné z DOI: <http://doi:10.1093/eurheartj/ehy339>. Go to original source... Go to PubMed...
    6. Corrao G, Parodi A, Zambon A et al. Reduced discontinuation of antihypertensive treatment by two-drug combination as first step. Evidence from daily life practice. J Hypertens 2010; 28(7): 1584-1590. Dostupné z DOI: <http://doi:10.1097/HJH.0b013e328339f9fa>. Go to original source... Go to PubMed...
    7. Mancia G, Zambon A, Soranna D et al. Factors involved in the discontinuation of antihypertensive drug therapy: an analysis from real life data. J Hypertens 2014; 32(8): 1708-1715; discussion 1716. Dostupné z DOI: <http://doi:10.1097/HJH.0000000000000222>. Go to original source... Go to PubMed...
    8. Mancia G, Asmar R, Amodeo C et al. Comparison of single-pill strategies first line in hypertension: perindopril/amlodipine versus valsartan/amlodipine. J Hypertens 2015; 33(2): 401-411. Dostupné z DOI: <http://doi:10.1097/HJH.0000000000000409>. Go to original source... Go to PubMed...
    9. Simons LA, Chung E, Ortiz M. Long-term persistence with single-pill, fixed-dose combination therapy versus two pills of amlodipine and perindopril for hypertension: Australian experience. Curr Med Res Opin 2017; 33(10): 1783-1787. Dostupné z DOI: <http://doi:10.1080/03007995.2017.1367275>. Go to original source... Go to PubMed...
    10. Rea F, Corrao G, Merlino L et al. Early cardiovascular protection by initial two-drug fixed-dose combination treatment vs. monotherapy in hypertension. Eur Heart J 2018; 39(40): 3654-3661. Dostupné z DOI: <http://doi:10.1093/eurheartj/ehy420>. Go to original source... Go to PubMed...
    11. Gradman AH, Parise H, Lefebvre P et al. Initial combination therapy reduces the risk of cardiovascular events in hypertensive patients: a matched cohort study. Hypertension 2013; 61(2): 309-318. Dostupné z DOI: <http://doi:10.1161/HYPERTENSIONAHA.112.201566>. Go to original source... Go to PubMed...
    12. Xu W, Goldberg SI, Shubina M et al. Optimal systolic blood pressure target, time to intensification, and time to follow-up in treatment of hypertension: population based retrospective cohort study. BMJ 2015; 350: h158. Dostupné z DOI: <http://doi:10.1136/bmj.h158>. Go to original source... Go to PubMed...
    13. Weir MR, Hsueh WA, Nesbitt SD et al. A titrate-to-goal study of switching patients uncontrolled on antihypertensive monotherapy to fixed-dose combinations of amlodipine and olmesartan medoxomil ± hydrochlorothiazide. J Clin Hypertens (Greenwich) 2011; 13(6): 404-412. Dostupné z DOI: <http://doi:10.1111/j.1751-7176.2011.00437>. Go to original source... Go to PubMed...
    14. Volpe M, Christian Rump L, Ammentorp B et al. Efficacy and safety of triple antihypertensive therapy with the olmesartan/amlodipine/hydrochlorothiazide combination. Clin Drug Investig 2012; 32(10): 649-664. Dostupné z DOI: <http://doi:10.2165/11636320-000000000-00000>. Go to original source... Go to PubMed...
    15. Fung V, Huang J, Brand R et al. Hypertension treatment in a medicare population: adherence and systolic blood pressure control. Clin Ther 2007; 29(5): 972-984. Dostupné z DOI: <http://doi:10.1016/j.clinthera.2007.05.010>. Go to original source... Go to PubMed...
    16. Bahiru E, de Cates AN, Farr MR et al. Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases. Cochrane Database Syst Rev 2017; 6;3:CD009868. Dostupné z DOI: <http://doi:10.1002/14651858.CD009868.pub3>. Go to original source... Go to PubMed...
    17. Toth K. [PIANIST Investigators]. Antihypertensive efficacy of triple combination perindopril/indapamide plus amlodipine in high-risk hypertensives: results of the PIANIST study (Perindopril-Indapamide plus AmlodipiNe in high rISk hyperTensive patients). Am J Cardiovasc Drugs 2014; 14(2):137-145. Dostupné z DOI: <http://doi:10.1007/s40256-014-0067-2>. Go to original source... Go to PubMed...
    18. Neutel JM, Smith DH. Hypertension management: rationale for triple therapy based on mechanisms of action. Cardiovasc Ther 2013; 31(5): 251-258. Dostupné z DOI: <http://doi:10.1111/1755-5922.12015>. Go to original source... Go to PubMed...
    19. Wright JT, jr, Williamson JD, Whelton PK et al. [SPRINT Research Group]. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med 2015; 373(22): 2103-2116. Dostupné z DOI: <http://doi:10.1056/NEJMoa1511939>. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.